Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alison M Gulbis

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2017
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid MalignanciesIssa F Khouri, Irina Fernandez Curbelo, Francesco Turturro, et al.
Transplantation and Cellular Therapy|June 13, 2025
Seizure prophylaxis and its impact on busulfan pharmacokinetics and dosing in a novel timed sequential protocol: MD Anderson experienceJitesh D Kawedia, Victoria W Handy, Alan L Myers, et al.
Leukemia & Lymphoma|February 28, 2022
Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitorsAkash Mukherjee, Denái R Milton, Elias J Jabbour, et al.
Bone Marrow Transplantation|October 17, 2024
Incidence of bacterial blood stream infections in patients with acute GVHDWhitney Wallis, Alison M Gulbis, Tao Wang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 13, 2017
Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic TransplantationMaria R Khouri, Elias J Jabbour, Alison M Gulbis, et al.
Bone Marrow Transplantation|December 23, 2017
Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefitBrittany Knick Ragon, Rohtesh S Mehta, Alison M Gulbis, et al.
Nature Reviews. Clinical Oncology|September 20, 2017
Chimeric antigen receptor T-cell therapy - assessment and management of toxicitiesSattva S Neelapu, Sudhakar Tummala, Partow Kebriaei, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 4, 2019
Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up ResultsKamal Chamoun, Denái R Milton, Celina Ledesma, et al.
Leukemia|July 27, 2021
Decrease post-transplant relapse using donor-derived expanded NK-cellsStefan O Ciurea, Piyanuch Kongtim, Doris Soebbing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2018
Updated Results of Rituximab Pre- and Post-BEAM with or without <sup>90</sup>Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell LymphomaJad Chahoud, Dawen Sui, William D Erwin, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2017
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid MalignanciesIssa F Khouri, Irina Fernandez Curbelo, Francesco Turturro, et al.
Transplantation and Cellular Therapy|June 13, 2025
Seizure prophylaxis and its impact on busulfan pharmacokinetics and dosing in a novel timed sequential protocol: MD Anderson experienceJitesh D Kawedia, Victoria W Handy, Alan L Myers, et al.
Leukemia & Lymphoma|February 28, 2022
Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitorsAkash Mukherjee, Denái R Milton, Elias J Jabbour, et al.
Bone Marrow Transplantation|October 17, 2024
Incidence of bacterial blood stream infections in patients with acute GVHDWhitney Wallis, Alison M Gulbis, Tao Wang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 13, 2017
Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic TransplantationMaria R Khouri, Elias J Jabbour, Alison M Gulbis, et al.
Bone Marrow Transplantation|December 23, 2017
Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefitBrittany Knick Ragon, Rohtesh S Mehta, Alison M Gulbis, et al.
Nature Reviews. Clinical Oncology|September 20, 2017
Chimeric antigen receptor T-cell therapy - assessment and management of toxicitiesSattva S Neelapu, Sudhakar Tummala, Partow Kebriaei, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 4, 2019
Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up ResultsKamal Chamoun, Denái R Milton, Celina Ledesma, et al.
Leukemia|July 27, 2021
Decrease post-transplant relapse using donor-derived expanded NK-cellsStefan O Ciurea, Piyanuch Kongtim, Doris Soebbing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2018
Updated Results of Rituximab Pre- and Post-BEAM with or without <sup>90</sup>Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell LymphomaJad Chahoud, Dawen Sui, William D Erwin, et al.
Pageof 3